<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1020-3397</journal-id>
<journal-title><![CDATA[Eastern Mediterranean Health Journal]]></journal-title>
<abbrev-journal-title><![CDATA[East. Mediterr. health j.]]></abbrev-journal-title>
<issn>1020-3397</issn>
<publisher>
<publisher-name><![CDATA[Alexandria: WHO, Regional Office for the Eastern Mediterranean]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1020-33972007000400010</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Abnormal Cambridge low-contrast grating sensitivity results associated with diabetic retinopathy as a potential screening tool]]></article-title>
<article-title xml:lang="fr"><![CDATA[Les anomalies au test optométrique CLCG (Cambridge low-contrast grating sensitivity) comme outil potentiel de dépistage de la rétinopathie diabétique]]></article-title>
<article-title xml:lang="ar"><![CDATA[&#1602;&#1610;&#1605;&#1577; &#1575;&#1604;&#1606;&#1578;&#1575;&#1574;&#1580; &#1594;&#1610;&#1585; &#1575;&#1604;&#1591;&#1576;&#1610;&#1593;&#1610;&#1577; &#1604;&#1575;&#1582;&#1578;&#1576;&#1575;&#1585; &#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1575;&#1604;&#1581;&#1586;&#1610;&#1586; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1548; &#1575;&#1604;&#1605;&#1589;&#1575;&#1581;&#1576;&#1577; &#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;&#1548; &#1603;&#1571;&#1583;&#1575;&#1577; &#1605;&#1581;&#1578;&#1605;&#1604;&#1577; &#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610; &#1607;&#1584;&#1575; &#1575;&#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604;]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abrishami]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Heravian]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Derakhshan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mousavi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Banaee]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Daneshvar]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moghaddam]]></surname>
<given-names><![CDATA[H.O.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Khatam Al-Anbia University Eye Hospital Department of Ophthalmology ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Mashhad, Islamic Republic of Iran Mashhad University of Medical Sciences IIOptometry Clinic]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2007</year>
</pub-date>
<volume>13</volume>
<numero>4</numero>
<fpage>810</fpage>
<lpage>818</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_arttext&amp;pid=S1020-33972007000400010&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_abstract&amp;pid=S1020-33972007000400010&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://eastern.mediterranean.scielo.org/scielo.php?script=sci_pdf&amp;pid=S1020-33972007000400010&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Contrast sensitivity is proposed as a potential screening tool for the early detection of diabetic retinopathy. A cross-sectional study was performed in a tertiary referral university eye centre. A total of 80 diabetes patients were recruited and tests were performed on 154 eyes. Contrast sensitivity was checked using Cambridge low-contrast grating. Abnormal contrast sensitivity was observed in 27.1% of eyes with diabetic retinopathy, compared with 9.0% in unaffected eyes, a statistically significant difference. Cambridge low-contrast grating is a potential screening tool for early detection of diabetic retinopathy by non-ophthalmologistsp.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[On suggère l’utilisation de la sensibilité au contraste comme outil potentiel de dépistage dans le cadre de la détection précoce de la rétinopathie diabétique. Un centre ophtalmologique universitaire de référence en soins tertiaires s’est livré à une étude transversale portant au total sur 80 patients diabétiques, ce qui représente l’exploration de 154 yeux. La sensibilité au contraste a été évaluée via un test CLCG (pour Cambridge low-contrast grating.) Une sensibilité anormale au contraste a été observée dans 27,1 % des yeux atteints de rétinopathie diabétique, contre 9,0 % des yeux indemnes de cette pathologie, écart qui représente une différence statistiquement significative. Le test CLCG constitue un outil potentiel de dépistage précoce de la rétinopathie diabétique utilisable par tout professionnel de santé non spécialisé en ophtalmologie.]]></p></abstract>
<abstract abstract-type="short" xml:lang="ar"><p><![CDATA[&#1575;&#1602;&#1578;&#1600;&#1585;&#1581;&#1578; &#1575;&#1604;&#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577; &#1604;&#1578;&#1603;&#1608;&#1606; &#1571;&#1583;&#1575;&#1577; &#1605;&#1581;&#1578;&#1605;&#1604;&#1577; &#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610; &#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;. &#1608;&#1602;&#1583; &#1571;&#1615;&#1580;&#1585;&#1610;&#1578; &#1583;&#1585;&#1575;&#1587;&#1577; &#1605;&#1587;&#1578;&#1593;&#1585;&#1590;&#1577; &#1601;&#1610; &#1605;&#1585;&#1603;&#1586; &#1604;&#1585;&#1593;&#1575;&#1610;&#1577; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1601;&#1610; &#1605;&#1587;&#1578;&#1588;&#1601;&#1609; &#1573;&#1581;&#1575;&#1604;&#1577; &#1578;&#1582;&#1589;&#1617;&#1615;&#1589;&#1610; &#1580;&#1575;&#1605;&#1593;&#1610;. &#1608;&#1578;&#1605; &#1575;&#1587;&#1578;&#1583;&#1593;&#1575;&#1569; 80 &#1605;&#1606; &#1605;&#1585;&#1590;&#1609; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610; &#1608;&#1576;&#1604;&#1594; &#1593;&#1583;&#1583; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1575;&#1604;&#1578;&#1610; &#1575;&#1582;&#1578;&#1615;&#1576;&#1600;&#1616;&#1585;&#1614;&#1578;&#1618; 154 &#1593;&#1610;&#1606;&#1575;&#1611;. &#1608;&#1578;&#1605; &#1601;&#1581;&#1589; &#1575;&#1604;&#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577; &#1576;&#1575;&#1587;&#1578;&#1582;&#1583;&#1575;&#1605; &#1581;&#1586;&#1610;&#1586; grating &#1603;&#1605;&#1576;&#1585;&#1610;&#1583;&#1580; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;. &#1608;&#1604;&#1608;&#1581;&#1592;&#1578; &#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577; &#1588;&#1575;&#1584;&#1577; &#1601;&#1610; 27.1% &#1605;&#1606; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1575;&#1604;&#1605;&#1589;&#1575;&#1576;&#1577; &#1576;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;&#1548; &#1576;&#1575;&#1604;&#1605;&#1602;&#1575;&#1585;&#1606;&#1600;&#1577; &#1605;&#1593; 9.0% &#1601;&#1610; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1594;&#1610;&#1585; &#1575;&#1604;&#1605;&#1589;&#1575;&#1576;&#1577;&#1548; &#1608;&#1607;&#1608; &#1601;&#1575;&#1585;&#1602; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615; &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611;. &#1608;&#1575;&#1587;&#1578;&#1606;&#1578;&#1580;&#1578; &#1575;&#1604;&#1583;&#1585;&#1575;&#1587;&#1577; &#1571;&#1606; &#1581;&#1586;&#1610;&#1586; &#1603;&#1605;&#1576;&#1585;&#1610;&#1583;&#1580; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606; &#1607;&#1608; &#1571;&#1581;&#1583; &#1575;&#1604;&#1571;&#1583;&#1608;&#1575;&#1578; &#1575;&#1604;&#1605;&#1581;&#1578;&#1605;&#1604;&#1577; &#1575;&#1604;&#1578;&#1610; &#1610;&#1605;&#1603;&#1606; &#1604;&#1594;&#1610;&#1585; &#1571;&#1591;&#1576;&#1575;&#1569; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1575;&#1587;&#1578;&#1582;&#1583;&#1575;&#1605;&#1607;&#1575; &#1601;&#1610; &#1575;&#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610; &#1575;&#1604;&#1605;&#1576;&#1603;&#1617;&#1616;&#1585; &#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;.]]></p></abstract>
</article-meta>
</front><body><![CDATA[ <p align="right"><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">RESEARCH    ARTICLES</font></b></p>     <p>&nbsp;</p>     <p><b><font face="Verdana, Arial, Helvetica, sans-serif" size="4">Abnormal Cambridge    low-contrast grating sensitivity results associated with diabetic retinopathy    as a potential screening tool </font></b></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Les anomalies    au test optométrique CLCG (Cambridge low-contrast grating sensitivity) comme    outil potentiel de dépistage de la rétinopathie diabétique </b></font></p>     <p>&nbsp;</p>     <p align="right"><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1602;&#1610;&#1605;&#1577;    &#1575;&#1604;&#1606;&#1578;&#1575;&#1574;&#1580; &#1594;&#1610;&#1585; &#1575;&#1604;&#1591;&#1576;&#1610;&#1593;&#1610;&#1577;    &#1604;&#1575;&#1582;&#1578;&#1576;&#1575;&#1585; &#1581;&#1587;&#1575;&#1587;&#1610;&#1577;    &#1575;&#1604;&#1581;&#1586;&#1610;&#1586; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590;    &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1548; &#1575;&#1604;&#1605;&#1589;&#1575;&#1581;&#1576;&#1577;    &#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577;    &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;&#1548; &#1603;&#1571;&#1583;&#1575;&#1577;    &#1605;&#1581;&#1578;&#1605;&#1604;&#1577; &#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610;    &#1607;&#1584;&#1575; &#1575;&#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604;</font></b></p>     <p align="right">&nbsp;</p>     <p align="right">&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>M. AbrishamiI;    J. Heravian<sup>I</sup>;  A. Derakhshan<sup>I</sup>, M. Mousavi<sup>I</sup>;    T. Banaee<sup>I</sup>; R.Daneshvar<sup>I</sup>;  H.O. Moghaddam<sup>II</sup>    </b></font></p>     ]]></body>
<body><![CDATA[<p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1605;&#1580;&#1610;&#1583;    &#1575;&#1576;&#1585;&#1610;&#1588;&#1605;&#1610;&#1548; &#1580;&#1608;&#1575;&#1583;    &#1607;&#1585;&#1608;&#1610;&#1575;&#1606;&#1548; &#1571;&#1603;&#1576;&#1585;    &#1583;&#1585;&#1582;&#1588;&#1575;&#1606;&#1548; &#1605;&#1610;&#1585;&#1606;&#1602;&#1610;    &#1605;&#1608;&#1587;&#1608;&#1610;&#1548; &#1578;&#1608;&#1603;&#1575; &#1576;&#1606;&#1575;&#1610;&#1610;&#1548;    &#1585;&#1575;&#1605;&#1610;&#1606; &#1583;&#1575;&#1606;&#1588;&#1608;&#1585;    &#1603;&#1575;&#1582;&#1603;&#1610;&#1548; &#1607;&#1575;&#1583;&#1610; &#1575;&#1587;&#1578;&#1575;&#1583;&#1610;    &#1605;&#1602;&#1583;&#1605;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Department    of Ophthalmology, Khatam Al-Anbia University Eye Hospital<sup>    <br>   II</sup>Optometry Clinic, Mashhad University of Medical Sciences, Mashhad, Islamic    Republic of Iran (Correspondence to M. Abrishami: <a href="mailto:abrishami.m@gmail.com">abrishami.m@gmail.com</a>)</font></p>     <p>&nbsp;</p>        <p ><sup>    <br>   </sup></p>    <hr size="1" noshade>     <p><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">ABSTRACT</font></b></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Contrast sensitivity    is proposed as a potential screening tool for the early detection of diabetic    retinopathy. A cross-sectional study was performed in a tertiary referral university    eye centre. A total of 80 diabetes patients were recruited and tests were performed    on 154 eyes. Contrast sensitivity was checked using Cambridge low-contrast grating.    Abnormal contrast sensitivity was observed in 27.1% of eyes with diabetic retinopathy,    compared with 9.0% in unaffected eyes, a statistically significant difference.    Cambridge low-contrast grating is a potential screening tool for early detection    of diabetic retinopathy by non-ophthalmologistsp&gt; </font></p> <hr size="1" noshade>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>R&Eacute;SUM&Eacute;</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> On suggère l’utilisation    de la sensibilité au contraste comme outil potentiel de dépistage dans le cadre    de la détection précoce de la rétinopathie diabétique. Un centre ophtalmologique    universitaire de référence en soins tertiaires s’est livré à une étude transversale    portant au total sur 80 patients diabétiques, ce qui représente l’exploration    de 154 yeux. La sensibilité au contraste a été évaluée via un test CLCG (pour    Cambridge low-contrast grating.) Une sensibilité anormale au contraste a été    observée dans 27,1 % des yeux atteints de rétinopathie diabétique, contre 9,0    % des yeux indemnes de cette pathologie, écart qui représente une différence    statistiquement significative. Le test CLCG constitue un outil potentiel de    dépistage précoce de la rétinopathie diabétique utilisable par tout professionnel    de santé non spécialisé en ophtalmologie.</font></p> <hr size="1" noshade>     ]]></body>
<body><![CDATA[<p align="right"><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1575;&#1604;&#1582;&#1604;&#1575;&#1589;&#1600;&#1577;</font></b>  </p>     <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&#1575;&#1602;&#1578;&#1600;&#1585;&#1581;&#1578;    &#1575;&#1604;&#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577;    &#1604;&#1578;&#1603;&#1608;&#1606; &#1571;&#1583;&#1575;&#1577; &#1605;&#1581;&#1578;&#1605;&#1604;&#1577;    &#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610; &#1575;&#1593;&#1578;&#1604;&#1575;&#1604;    &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;.    &#1608;&#1602;&#1583; &#1571;&#1615;&#1580;&#1585;&#1610;&#1578; &#1583;&#1585;&#1575;&#1587;&#1577;    &#1605;&#1587;&#1578;&#1593;&#1585;&#1590;&#1577; &#1601;&#1610; &#1605;&#1585;&#1603;&#1586;    &#1604;&#1585;&#1593;&#1575;&#1610;&#1577; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606;    &#1601;&#1610; &#1605;&#1587;&#1578;&#1588;&#1601;&#1609; &#1573;&#1581;&#1575;&#1604;&#1577;    &#1578;&#1582;&#1589;&#1617;&#1615;&#1589;&#1610; &#1580;&#1575;&#1605;&#1593;&#1610;.    &#1608;&#1578;&#1605; &#1575;&#1587;&#1578;&#1583;&#1593;&#1575;&#1569; 80 &#1605;&#1606;    &#1605;&#1585;&#1590;&#1609; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;    &#1608;&#1576;&#1604;&#1594; &#1593;&#1583;&#1583; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606;    &#1575;&#1604;&#1578;&#1610; &#1575;&#1582;&#1578;&#1615;&#1576;&#1600;&#1616;&#1585;&#1614;&#1578;&#1618;    154 &#1593;&#1610;&#1606;&#1575;&#1611;. &#1608;&#1578;&#1605; &#1601;&#1581;&#1589;    &#1575;&#1604;&#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577;    &#1576;&#1575;&#1587;&#1578;&#1582;&#1583;&#1575;&#1605; &#1581;&#1586;&#1610;&#1586;    grating &#1603;&#1605;&#1576;&#1585;&#1610;&#1583;&#1580; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590;    &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606;. &#1608;&#1604;&#1608;&#1581;&#1592;&#1578;    &#1581;&#1587;&#1575;&#1587;&#1610;&#1577; &#1578;&#1576;&#1575;&#1610;&#1606;&#1610;&#1577;    &#1588;&#1575;&#1584;&#1577; &#1601;&#1610; 27.1% &#1605;&#1606; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606;    &#1575;&#1604;&#1605;&#1589;&#1575;&#1576;&#1577; &#1576;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604;    &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577; &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;&#1548;    &#1576;&#1575;&#1604;&#1605;&#1602;&#1575;&#1585;&#1606;&#1600;&#1577; &#1605;&#1593;    9.0% &#1601;&#1610; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606; &#1594;&#1610;&#1585;    &#1575;&#1604;&#1605;&#1589;&#1575;&#1576;&#1577;&#1548; &#1608;&#1607;&#1608;    &#1601;&#1575;&#1585;&#1602; &#1610;&#1615;&#1593;&#1618;&#1578;&#1614;&#1583;&#1617;&#1615;    &#1576;&#1607; &#1573;&#1581;&#1589;&#1575;&#1574;&#1610;&#1575;&#1611;. &#1608;&#1575;&#1587;&#1578;&#1606;&#1578;&#1580;&#1578;    &#1575;&#1604;&#1583;&#1585;&#1575;&#1587;&#1577; &#1571;&#1606; &#1581;&#1586;&#1610;&#1586;    &#1603;&#1605;&#1576;&#1585;&#1610;&#1583;&#1580; &#1575;&#1604;&#1605;&#1606;&#1582;&#1601;&#1590;    &#1575;&#1604;&#1578;&#1576;&#1575;&#1610;&#1606; &#1607;&#1608; &#1571;&#1581;&#1583;    &#1575;&#1604;&#1571;&#1583;&#1608;&#1575;&#1578; &#1575;&#1604;&#1605;&#1581;&#1578;&#1605;&#1604;&#1577;    &#1575;&#1604;&#1578;&#1610; &#1610;&#1605;&#1603;&#1606; &#1604;&#1594;&#1610;&#1585;    &#1571;&#1591;&#1576;&#1575;&#1569; &#1575;&#1604;&#1593;&#1610;&#1608;&#1606;    &#1575;&#1587;&#1578;&#1582;&#1583;&#1575;&#1605;&#1607;&#1575; &#1601;&#1610;    &#1575;&#1604;&#1578;&#1581;&#1585;&#1617;&#1616;&#1610; &#1575;&#1604;&#1605;&#1576;&#1603;&#1617;&#1616;&#1585;    &#1604;&#1575;&#1593;&#1578;&#1604;&#1575;&#1604; &#1575;&#1604;&#1588;&#1576;&#1603;&#1610;&#1577;    &#1575;&#1604;&#1587;&#1603;&#1617;&#1614;&#1585;&#1610;. </font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Diabetes mellitus    and its complications have confronted the developing as well as the industrialized    world as a major public health problem. Despite being the leading cause of blindness    in Americans between 20 and 64 years, the ocular complications of diabetes are    preventable and treatable in the early stages of the disease &#91;<i>1-3</i>&#93;. Screening    and monitoring programmes are agreed to be the most effective future means of    minimizing the complications associated with diabetes mellitus. Besides the    social benefits of living more years with adequate visual performance, there    is a substantial cost saving by early detection of significant retinopathy using    effective screening and monitoring methods &#91;<i>4-7</i>&#93;. Thus, a reliable, quick    and inexpensive test for detection of early dysfunction is of vital importance    to primary and shared care programmes. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Visual acuity charts    only measure the high frequency component of the contrast sensitivity function    and are markedly affected by small amounts of defocus &#91;<i>8</i>&#93;. Loss of low-frequency    contrast sensitivity has been reported to reduce the ability to recognize faces    and background images. It may also affect recognition of postures and movement    &#91;<i>9</i>&#93;. Therefore, the contrast sensitivity function curve gives additional    information about a subject’s visual relationship to the environment and provides    a more comprehensive description of visual performance than visual acuity alone.    Visual acuity can be normal in some ocular diseases, including optic neuritis    and glaucoma, where contrast sensitivity can be significantly decreased &#91;<i>10,11</i>&#93;.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There is still    controversy about the effectiveness of contrast sensitivity as a screening tool    for diabetic retinopathy &#91;<i>12-17</i>&#93;. The present study investigated the    use of Cambridge low-contrast grating as a potential screening tool for early    detection of diabetic retinopathy by non-ophthalmologists, focusing on changes    of low-contrast sensitivity in different stages of diabetic retinopathy.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Methods</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">This was a cross-sectional    study of 95 patients with diabetes, referred to the ophthalmology clinic of    Imam Reza General Hospital, Mashhad, Islamic Republic of Iran between May 2003    and August 2003. The study protocol was reviewed and approved by the ethics    committee of the Research Assembly of Mashhad University of Medical Sciences.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The exclusion criteria    were: significant ocular diseases beside diabetic retinopathy, including cataract,    glaucoma, and optic nerve diseases, amblyopia, macular diseases, history of    previous ocular surgery or photocoagulation and systemic diseases other than    diabetes. After initial evaluations, 15 patients were excluded. Thus a total    number of 154 eyes of 80 patients were evaluated.  </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">For each patient,    a questionnaire was completed about the type and duration of diabetes, mode    of control and last blood glucose level, checked in the past month.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Objective refraction    was done with a Topcon RM-A6500 autorefractometer and refined with manual retinoscopy    (Hein HSR2) and axis refinement (Jackson cross-cylinder). Afterwards, the best    corrected visual acuity was determined on a subjective basis. The visual acuity    was checked with an illiterate E-chart. With the best correction of the refractive    error, the contrast sensitivity was evaluated with a Cambridge low-contrast    grating system. The test was done under a standard luminance of 100 cd/m<sup>2</sup>,    as described previously &#91;<i>18</i>&#93;. The chart luminance was regularly    checked using a spot photometer. The visual acuity and contrast sensitivity    were checked independently by an examiner who was blind to the results of other    tests. Finally, slit-lamp evaluation of the anterior segment was used to exclude    significant anterior segment pathology and narrowness of angle. Indirect ophthalmoscopy    (fully-dilated) and non-contact slit lamp funduscopy were done by the same ophthalmologist.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">As described by    the Early Treatment Diabetic Retinopathy Study &#91;<i>19</i>&#93; the patients were    classified as having no diabetic retinopathy, mild, moderate, severe, or very    severe non-proliferative diabetic retinopathy (NPDR), early proliferative diabetic    retinopathy (PDR), high-risk characteristic PDR (HRC-PDR), and/or clinically    significant macular enema (CSME); the latter 2 were among the exclusion criteria.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Considering <i>P</i>    &lt; 0.05 significant, Pearson chi-squared, Student <i>t</i>-test and analysis    of variance were used in analysing the relationships. A regression analysis    was done to describe the correlation between visual acuity and Cambridge low-contrast    grating measurements. <i>SPSS</i>, version 11.5 was used for all statistical    calculations.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The patients’ characteristics    are presented in <a href="#tab01">Table 1</a>. There was a statistically significant    difference in the age of patients (<i>P</i> = 0.031) and duration of diabetes    (<i>P</i> &lt; 0.0001) for patients with and without diabetic retinopathy. Sex    was not a significant determinant for diabetic retinopathy (<i>P</i> &lt; 0.50).</font></p>     <p><a name="tab01"></a></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a09tab01.gif"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Abnormal contrast    sensitivity was observed in 27.1% of eyes with diabetic retinopathy, compared    with 9.0% in unaffected eyes. The mean contrast sensitivity in the diabetic    retinopathy group was 217.60 cps compared with a mean of 309.30 cps in the group    without diabetic retinopathy (<a href="#tab02">Tables 2</a> and <a href="#tab03">3</a>).    </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There was    a statistically significant correlation between the presence of diabetic retinopathy    and poor contrast sensitivity (<i>P</i> &lt; 0.01). The contrast sensitivity    deteriorated with more advanced diabetic retinopathy (<a href="#tab04">Table    4</a>), but this was not statistically significant (<i>P</i> = 0.349, analysis    of variance). However, there was a significant correlation between the duration    of diabetes and the level of contrast sensitivity (Pearson <i>r</i> = -0.216,    <i>P</i> = 0.007) (<a href="#fig01">Figure 1</a>).</font></p>     <p><a name="tab02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a09tab02.gif"></p>     <p>&nbsp;</p>     <p><a name="tab03"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/emhj/v13n4/a09tab03.gif"></p>     <p>&nbsp;</p>     <p><a name="tab04"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a09tab04.gif"></p>     <p>&nbsp;</p>     <p><a name="fig01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a09fig01.jpg"></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There was a statistically    significant correlation between the decrease in visual acuity and contrast sensitivity    in eyes with diabetic retinopathy (<i>P</i> = 0.049) (<a href="#fig02">Figure    2</a>).</font></p>     <p><a name="fig02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/emhj/v13n4/a09fig02.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b>    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">After 20 years,    almost 99% of patients with type 1 diabetes and 60% with type 2 diabetes will    have some degree of diabetic retinopathy &#91;<i>19</i>&#93;.  Beside the duration of    disease, the age at onset is another important determinant of diabetic retinopathy:    diabetic retinopathy is much more common in juvenile onset diabetes and this    has major socioeconomic consequences. In one study, 86% of blindness in patients    with a lower age of diabetes onset (age &lt; 30 years) was attributable to diabetic    retinopathy &#91;<i>20</i>&#93;. Prevention and interruption of this process depends    on early detection and effective screening methods.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The success of    any screening test obviously depends upon its ability to differentiate patients    with the problem in question from other patients &#91;<i>21</i>&#93;. Regarding diabetic    retinopathy, the ability of tests to differentiate those known to have diabetes    mellitus but no retinopathy and those diabetes patients who have already developed    diabetic retinopathy is of particular interest &#91;<i>16</i>&#93;. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There is a marked    controversy about the loss of contrast sensitivity in diabetes patients without    retinopathy and the spatial frequencies at which losses occur in the presence    of retinopathy. Early studies, such as that by Arden and Jacobson, used photographic    plates to measure contrast sensitivity in diabetes patients with background    diabetic retinopathy and another group with no retinopathy &#91;<i>22</i>&#93;. They    found abnormal contrast sensitivity between normal and diabetes patients with    background retinopathy, but there was no difference in contrast sensitivity    between normal and diabetes patients without background retinopathy. Ghafour    et al., using a similar method, also found that diabetes patients with background    retinopathy had abnormal contrast sensitivity &#91;<i>23</i>&#93;. Unlike Arden and    Jacobson, however, they reported that diabetes patients without retinopathy    had abnormal contrast sensitivity at mid-frequencies. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Hyvarinen et al.    measured individual contrast sensitivity functions in 19 patients with diabetes    with different degrees of diabetic retinopathy &#91;<i>24</i>&#93;. They reported that    patients with 20/20 acuity and background retinopathy showed abnormalities in    contrast sensitivity. They also suggested that contrast sensitivity fluctuates    with blood sugar levels in diabetes, becoming reduced in the presence of hypoglycaemia.    </font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Sokol et al. measured    contrast sensitivity in type 1 and 2 diabetes patients with minimal or no diabetic    retinopathy &#91;<i>25</i>&#93;. They found that type 2 diabetes patients with no retinopathy    had abnormal contrast sensitivity at high spatial frequencies, while those with    background diabetic retinopathy demonstrated abnormal contrast sensitivity at    all tested spatial frequencies. Several authors found a significant loss of    contrast sensitivity in early diabetic retinopathy groups at mid-to-high spatial    frequencies using the Vistech VCTS chart &#91;<i>14,26,27</i>&#93;. Low-to-medium spatial    frequency changes have also been reported to occur and it has been suggested    that visual acuity measures alone may therefore be unreliable as a clinical    indicator of loss of visual function &#91;<i>28</i>&#93;.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">To the best of    our knowledge, this is the first study using Cambridge low-contrast grating    in diabetic patients. We found a statistically significant difference in low    spatial frequency contrast sensitivity between diabetics with and without retinopathy.    This means that Cambridge low-frequency grating may be a potential screening    tool for early retinopathic changes in diabetic patients. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">There are a number    of hypotheses about the potential causes of diminished contrast sensitivity    in diabetic patients. Regan and Neima have reported a correlation between ischaemia    of the parafoveal arcade using intravenous fluorescein angiograms and abnormal    letter chart results &#91;<i>12</i>&#93;. This suggests that the pathophysiology responsible    for contrast sensitivity loss in diabetes is due to functional loss of retinal    ganglion cell dendrites, secondary to retinal ischaemia. Another factor, which    may explain the etiology of reduced contrast sensitivity in diabetic eyes, is    the diameter and extent of the foveal avascular zone &#91;<i>1</i>&#93;. Arend et al.    found that the diameters of the foveal avascular zone and the perifoveal intercapillary    area are significantly correlated with contrast sensitivity at mid-spatial frequencies    &#91;<i>29</i>&#93;. Bresnick et al. revealed that the area of the foveal avascular    zone in diabetics with non-proliferative diabetic retinopathy is significantly    larger than healthy non-diabetic controls &#91;<i>30</i>&#93;. When the dimension of    the foveal avascular zone progresses to greater than 1000 µm, visual acuity    is usually diminished. This degree of destruction of the parafoveal capillary    net is usually confined to cases of proliferative retinopathy. However, functional    correlation of contrast sensitivity and foveal avascular zone extent is difficult    because the diameter of the foveal avascular zone of a normal eye can vary considerably    (350-750 µm) &#91;<i>31</i>&#93;, and one cannot predict with accuracy the potential    contrast sensitivity based solely on the appearance of the foveal avascular    zone.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The rate of retinal    blood flow may also affect the degree of contrast sensitivity loss. Several    investigators have demonstrated enhanced retinal blood flow rates in diabetes    patients with background retinopathy &#91;<i>32-37</i>&#93;. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">It is suggested    that the diminished contrast sensitivity in diabetic patients is partially reversible    by breathing oxygen, and is therefore probably the result of retinal hypoxia    &#91;<i>38</i>&#93;. However, an improvement of contrast sensitivity does not occur    after pan-retinal photocoagulation treatment, which implies that the reduction    of contrast sensitivity is irreversible &#91;<i>17</i>&#93;.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclusion</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">We found a significant    diminution in contrast sensitivity in patients with early     <br>   diabetic retinopathy compared with those without diabetic retinopathy. There    was also a progressive deterioration of contrast sensitivity in more advanced    stages of diabetic retinopathy. The findings are contrary to a number of previous    studies, which found no statistically significant difference between diabetics    without retinopathy and those with background retinopathy. This may be due to    the use of a more sensitive tool in evaluation of contrast sensitivity in current    study. It has been shown that the decrease in contrast sensitivity is more remarkable    in low spatial frequencies. Hence, the Cambridge low frequency grating is a    potential tool for the screening of early stages in diabetic retinopathy. However,    larger, prospective studies will be needed to further investigate the sensitivity    and specificity of the test as a screening tool.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">We are indebted    to the Research Assembly of the Mashhad University of Medical Sciences for its    financial support of the project. Our sincerest thanks go to Ms Sherafat Javaheri    for participation in performing the contrast sensitivity tests. We are also    grateful to Dr H. Esmaili for his assistance in statistical analysis.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1.   Flynn HW Jr,    Smiddy WE, eds. <i>Diabetes and ocular disease: past, present, and future therapies.    </i>San Francisco, American Academy of Ophthalmology, 2000 (Ophthalmology monograph    14).</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000952&pid=S1020-3397200700040001000001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2.   Intensive    blood-glucose control with sulphonylureas or insulin compared with conventional    treatment and risk of complications in patients with type 2 diabetes (UKPDS    33).  United Kingdom Prospective Diabetes Study Group. <i>Lancet</i>, 1998,    352:837-53.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3.   Tight blood    pressure control and risk of macrovascular and microvascular complications in    type 2 diabetes: UKPDS 38. United Kingdom Prospective Diabetes Study Group.    <i>British medical journal</i>, 1998, 317:703-13.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4.   Early Treatment    Diabetic Retinopathy Study Research Group. Results from the Early Treatment    of Diabetic Retinopathy Study. <i>Ophthalmology</i>, 1991, 98:739-840.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5.   Dasbach EJ    et al. Cost-effectiveness of strategies for detecting diabetic retinopathy.    <i>Medical care</i>, 1991, 29:20-39.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6.   Javitt JC    et al. Detecting and treating retinopathy in patients with type I diabetes mellitus.    <i>Ophthalmology</i>, 1990, 97:483-93.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7.   Cooke JB,    Cochrane AL. A practical guide to low vision management of patients with diabetes.    <i>Clinical &amp; experimental optometry</i>, 2001, 84:155-61.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8.   Bradley A    et al. Effect of spherical and astigmatic defocus on acuity and contrast sensitivity:    a comparison of three clinical charts. <i>Optometry and vision science</i>,    1991, 68:418-26.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9.   Sekuler R,    Hutman LP, Owsley CJ. Human ageing and spatial vision. <i>Science</i>, 1980,    209:1255-6.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10.  Zimmern RL,    Campbell FW, Wilkinson IMS. Subtle disturbances of vision after optic neuritis    elicited by studying contrast sensitivity. <i>Journal of neurology, neurosurgery,    and psychiatry</i>, 1979, 42:407-12.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11.  Ross JE, Bron    AJ, Clarke DD. Contrast sensitivity and visual disability in chronic simple    glaucoma. <i>British journal of ophthalmology</i>, 1984, 68:821-7.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12.  Regan D, Neima    D. Low contrast letter charts in early diabetic retinopathy, ocular hypertension,    glaucoma, and Parkinson’s disease. <i>British journal of ophthalmology</i>,    1984, 68:885-9.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13.  Della Sala    S et al. Impaired contrast sensitivity in diabetic patients with and without    retinopathy. A new technique for rapid assessment. <i>British journal of ophthalmology</i>,    1985, 69:136-42.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14.  Trick GL et    al. The relationship between hue discrimination and contrast sensitivity deficits    in patients with diabetes mellitus. <i>Ophthalmology</i>, 1988, 95:693-8.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15.  Khosla PK,    Talwar D, Tewaari HK. Contrast sensitivity changes in background diabetic retinopathy.    <i>Canadian journal of ophthalmology</i>, 1991, 26:7-11.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16.  Ismail GM,    Whitaker D. Early detection of changes in visual function in diabetes mellitus.    <i>Ophthalmic &amp; physiological optics</i>, 1998, 18:3-12.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17.  Mackie SW,    Walsh G. Contrast and glare sensitivity in diabetic patients with and without    pan-retinal photocoagulation. <i>Ophthalmic &amp; physiological optics</i>,    1998, 18:173-81.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18.  Jones HS,    Moseley MJ, Thompson JR. Reliability of the Cambridge low contrast gratings. <i>Ophthalmic &amp; physiological optics</i>, 1994, 14(3):287-9.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>19.  Retina    and vitreous, Section 9. Basic and clinical science course. </i>San Francisco,         American Academy of Ophthalmology, 2004/05:99-119.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20.  Klein R et    al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence    and risk factors of diabetic retinopathy when age at diagnosis is less than    30 years. <i>Archives of ophthalmology</i>, 1984, 102:520-6.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21.  Ivers RQ et    al. Sensitivity and specificity of tests to detect eye disease in an older population.    <i>Ophthalmology</i>, 2001, 108:968-75.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22.  Arden GB,    Jacobson JJ. A simple grating test for contrast sensitivity: preliminary results    indicate value in screening for glaucoma. <i>Investigative ophthalmology &amp;    visual science</i>, 1978, 17:23-5.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23.  Ghafour IM    et al. Contrast sensitivity in diabetic subjects with and without retinopathy.    <i>British journal of ophthalmology</i>, 1982, 66:492-5.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24.  Hyvarinen    L, Laurinen P, Rovamo J. Contrast sensitivity in evaluation of visual impairment    due to diabetes. <i>Acta ophthalmologica</i>, 1983, 61:94-101.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25.  Sokol S et    al. Contrast sensitivity in diabetics with and without background retinopathy.    <i>Archives of ophthalmology</i>, 1985, 103:51-4.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26.  Banford D    et al. Longitudinal study of visual functions in young insulin dependent diabetics.    <i>Ophthalmic &amp; physiological optics</i>, 1994, 14:339-46.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27.  Bangstad HJ    et al. Impaired contrast sensitivity in adolescents and young type 1 (insulin-dependent)    diabetic patients with microalbuminuria. <i>Acta ophthalmologica</i>, 1994,    72:668-73.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28.  Di Leo MA    et al. Presence and further development of retinal dysfunction after 3-year    follow up in IDDM patients without angiographically documented vasculopathy.    <i>Diabetologia</i>, 1994, 37:911-6.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29.  Arend O et    al. Contrast sensitivity loss is coupled with capillary dropout in patients    with diabetes. <i>Investigative ophthalmology &amp; visual science</i>, 1997,    38:1819-24.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30.  Bresnick GH    et al. Abnormalities of the foveal avascular zone in diabetic retinopathy. <i>Archives    of ophthalmology</i>, 1984, 102:1086-293.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31.  Sleightholm    MA, Arnold J, Kohner EM. Diabetic retinopathy: 1. The measurement of intercapillary    area in normal retinal angiograms. <i>Journal of diabetic complications</i>,    1988, 11:113-6.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32.  Kohner EM.    Problems of retinal blood flow in diabetes. <i>Diabetes</i>, 1976, 25:839-44.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33.  Soeldner JS,    Christacopulos PD, Gleason RE. Mean retinal circulation time as determined by    fluorescein angiography in normal prediabetic and chemical-diabetic subjects.    <i>Diabetes</i>, 1976, 25:903-8.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34.  Findl O et    al. Ocular haemodynamics and colour contrast sensitivity in patients with type    1 diabetes. <i>British journal of ophthalmology</i>, 2000, 84:493-8.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35.  Sinclair SH    et al. Retinal vascular autoregulation in diabetes mellitus. <i>Ophthalmology</i>,    1982, 89:748-50.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36.  Fallon TJ,    Chowiencyzk P, Kohner EM. Measurement of retinal blood flow in diabetics by    blue-light entoptic phenomenon. <i>British journal of ophthalmology</i>, 1986,    70:43-6.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37.  Rand LI et    al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy.    <i>New England journal of medicine</i>, 1985, 313:1433-8.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38.  Arden GB,    Wolf JE, Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence    and a linking hypothesis. <i>Vision research</i>, 1998, 38:1723-9.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>&nbsp;</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Received: 16/03/05;    accepted: 12/04/05 </font></p>      ]]></body>
<REFERENCES></REFERENCES<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[HW Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Smiddy]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes and ocular disease: past, present, and future therapies]]></source>
<year>2000</year>
<volume>14</volume>
<publisher-loc><![CDATA[San Francisco ]]></publisher-loc>
<publisher-name><![CDATA[American Academy of Ophthalmology]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
